ERBB2 amplification and/or overexpression has been reported in 15-30 % of human breast cancer malignancies and has been shown to contribute in an increased risk of recurrent disease and poor clinical outcome by promoting many cellular functions including DNA synthesis, cell proliferation, and cell survival. This evidence concerns the gene ERBB2 and breast carcinoma.